GC
DNLI icon

Grace Capital’s Denali Therapeutics DNLI Stock Holding History

Grace Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$235K – 166
2021
Q2 		$235K Hold
3,000
– – 0.16% 124
2021
Q1 		$171K Hold
3,000
– – 0.11% 157
2020
Q4 		$251K Buy
+3,000
New +$181K 0.16% 135

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Grace Capital's DNLI Position: Q3 2021 in Review

Grace Capital sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 3,000 shares — an estimated $235K sold.

Grace Capital first reported a position in DNLI in Q4 2020 and held it in 3 quarters. The position peaked at $251K in Q4 2020. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Grace Capital reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Grace Capital sold 3,000 Denali Therapeutics shares in Q3 2021, an estimated $235K.
  • Grace Capital first reported a position in Denali Therapeutics in Q4 2020 and held it in 3 quarters.
  • Grace Capital's Denali Therapeutics position peaked at $251K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Grace Capital's 13F filing for Q3 2021, filed 8 Nov 2021.